Hepatitis Market


Overview


Hepatitis is the inflammation of the liver. The condition can be limited to self or can advance to scarring, cirrhosis or liver cancer. Hepatitis viruses are the most common origin of Hepatitis in all over the world. Sometimes, other infections, toxic substances (e.g. alcohol, certain drugs), and autoimmune diseases can also cause Hepatitis. 

“Nearly 1 million people die every year worldwide due to Hepatitis”

Hepatitis types

Hepatitis classification is based on the two types. One is acute if the condition lasts for less than six months and chronic when the condition persists for more than six months. Based on disease type, the hepatitis therapeutics market is segmented into A, B, C, and others. The other segment covers the hepatitis market that estimates for hepatitis D and E, which occur rarely compared to the other three conditions. 

The access to hepatitis treatments of this disease has been limited to people who have a high-income level owing to high drug price, which might act as a restraining factor for the hepatitis market. The hepatitis market dynamics will change globally because of the introduction of generic versions of drugs. 

Hepatitis market

The global therapeutics hepatitis market size was estimated at USD 19 billion in 2016 and is pegged at a CAGR of 3% during the forecast period for hepatitis market size forecast. There are a few prominent factors that are expected to boost the hepatitis market; they are growing viral Hepatitis prevalence, rise in the number of autoimmune diseases, and the surge in healthcare expenditures across the globe. 

The therapeutics hepatitis market share analysis is mainly dominated by North America, followed by Europe and the Asia Pacific. In 2016, the North America hepatitis market forecast accounted for 43 % of revenue mainly due to the high demand in the U.S., relatively higher affordability of patient population, and awareness about advance therapeutics in the region. 

Hepatitis B Virus Overview

One of the viruses is the Hepatitis B Virus (HBV) that causes Hepatitis B, which is a life-threatening liver infection. It is a significant concern and a significant global health problem. It can be an acute infection or a chronic infection. Chronic Hepatitis B Virus infection is the leading cause of chronic Hepatitis and advanced-stage liver diseases, including cirrhosis and hepatocellular carcinoma (HCC). Hepatitis B virus is a blood-borne and sexually-transmitted virus, which is acquired by percutaneous and mucosal exposure to blood or/ and body fluids of an infected person. The clinical manifestations of Hepatitis from different origins may be quite similar.

Hepatitis B Virus Infection is estimated to have 786,000 deaths and the vast majority being attributable to liver cancer (341,000 deaths) and cirrhosis (312,000 deaths). Hepatitis B Virus infection ranks 15th among all causes of human mortality. Around two billion people globally have been infected with the Hepatitis B Virus infection and about 360 million live with chronic Hepatitis B infection. The Hepatitis B Virus prevalence in the general population is heterogeneous in Europe, ranging 0.1-7 % depending on the country. The Hepatitis B Virus global prevalence varies widely. It ranges from 0.5 % in areas of low endemicity (e.g., North America and some Western European countries) to rates above 8% in the highly endemic countries of Sub- Saharan Africa and East Asia.

Hepatitis B virus market

Now taking into consideration of Hepatitis B virus market, it is dominated by chronic Hepatitis B medication, which focuses on viral suppression and includes two therapy classes, oral nucleoside analogues (NUC) – Nucleoside/Nucleotide Reverse Transcriptase Inhibitors (NRTIs) and pegylated interferon (PEG-IFN). For acute hepatitis B infection, no specific treatment is available; only care is focused on maintaining comfort and required nutritional balance, including replacement of fluids (lost due to vomiting), etc.

Many companies are developing drugs for Hepatitis B Virus market treatment. DelveInsight is one such company that prepares market reports, pipeline reports, and epidemiology reports. It proffers a detailed overview of the Hepatitis B Virus market and an in-depth comprehension of the historical and forecasted Hepatitis B Virus market epidemiology. It shows Hepatitis B Virus market treatment patterns, potential upcoming drugs and also recognises the best of the Hepatitis B Virus market opportunities by showing the current and forecasted Hepatitis B Virus market revenue, trends of sales, and uptake of drugs during the study period from 2017-2028. The Hepatitis B Virus market report also proffers in-depth analysis of the disease overview by including details like disease definition, classification, symptoms, aetiology, pathophysiology and diagnostic trends. The exhaustive details about Hepatitis B Virus market treatment algorithms and treatment guidelines in the United States, Europe, and Japan are also provided in the report.




Comments

Post a Comment

Popular posts from this blog

Tenosynovial Giant Cell Tumors (TSGCTs) Market Research Report 2030 | Tenosynovial Giant Cell Tumors (TSGCTs) Market

Image
Tenosynovial Giant Cell Tumors   are a type of neoplasm that affects synovial-lined tendon sheaths, synovial joints, and surrounding soft tissue. Locally aggressive benign tissue lesions are defined by synovial lining inflammation in joints and tendons. Overexpression of the colony-stimulating factor 1 receptor is thought to cause these tumors to form. Giant cell tumors of the tendon sheath (GCTTS), pigmented villonodular tumors (PVNTS), extra-articular pigmented villonodular tumors of the tendon sheath, and localized or focal nodular synovitis are all terms used to describe TSGCTs. Tenosynovial Giant Cell Tumors Causes Translocation is an alteration to a chromosome that causes Tenosynovial Giant Cell Tumors. A chromosome segment breaks off and moves around. The cause of these translocations is unknown. The genetic code for making proteins is stored on chromosomes. A protein termed colony-stimulating factor 1 is produced in excess due to the translocation (CSF1). This protein attracts
Read more

Functional Dyspepsia Market Research Report 2030 | Functional Dyspepsia Market

Image
  Functional dyspepsia   is a term for recurring signs and symptoms of indigestion that have no apparent cause. Functional dyspepsia is also called non-ulcer stomach pain or non-ulcer dyspepsia. It's not clear what causes functional dyspepsia. Doctors consider it a functional disorder, which means that routine testing may not show any abnormalities. Hence, it is diagnosed based on symptoms. Functional Dyspepsia Signs and Symptoms  Functional dyspepsia is common and can be long-lasting — although signs and symptoms are mostly intermittent. These signs and symptoms resemble those of an ulcer, discomfort in your upper abdomen, often accompanied by bloating, belching, and nausea, An early feeling of fullness (satiety) when eating, Pain in the stomach that may sometimes occur unrelated to meals, or maybe relieved with meals. Functional Dyspepsia Epidemiology According to an article by Madisch et al. (2018), Functional Dyspepsia is one of the common functional disorders, with a prevalenc
Read more

Fibrodysplasia Ossificans Progressiva Market Research Report 2030 | Fibrodysplasia Ossificans Progressiva Market

Image
  Fibrodysplasia ossificans progressiva   is a disorder in which the skeleton, muscles, and connective tissues, such as tendons and ligaments, are replaced by bone (ossified). This position was to lead to the formation of the bones of the skeleton (extra-skeletal or heterotopic bone) that constrains movement. Fibrodysplasia ossificans progressiva Causes Fibrodysplasia ossificans progressiva is called a mutation in the ACVR1 gene. This gene is involved in bone growth and development. Mutations, and the possibility of a disorderly development. The gene can be inherited from a parent, but in most cases, the, is a new mutation, a person with a less-than-a family history of the disease. As a parent, they have a 50% chance of passing it on to their children. Fibrodysplasia ossificans progressiva Sign and Symptoms The  Fibrodysplasia ossificans progressiva  symptoms begin in the first decade of life with episodes of painful inflammatory soft tissue swellings. Gradually, there occurs restricti
Read more